Selection of CD34+ cells from cryopreserved PBPC can be significantly improved by the addition of recombinant human DNase (Pulmozyme)

Cytotherapy

Volumn 1, Issue 1, 1999, Pages 31-40

  Alcorn, M J ^a   Richmond, L J ^a   Farrell, E ^a   Barr, J ^a   Pearson, C ^a   Schupp, R ^b   Franklin, I M ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b Baxter Cellular Therapies   (Germany)

Author keywords

CD34 selection; Cryopreserved PBPC; Recombinant human DNase

Indexed keywords

EID: 0001939012     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/0032472031000141297     Document Type: Article

References (29)

1. Fernand J-P, Chevret S, Ravaud P et al. High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a Phase II trial involving 63 patients. Blood 1993;82:2005-9.
2. Bensinger WI, Rowley SD, Demirer T et al. High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. J Clin Oncol 1996;14:1447-56.
3. Rapoport AP, Rowe JM, Kouides PA et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma; value of pretransplant disease status for predicting outcome. J Clin Oncol 1993;11:2351-61.
4. Pettengel R, Radford JA, Morgenstern GR et al. Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma. J Clin Oncol 1996;14:586-92.
5. Moss TJ, Sanders DG, Lasky LC et al. Contamination of peripheral blood stem cell harvests by circulating neuroblastoma cells. Blood 1990;76:1879-83.
6. Ross AA, Cooper BW, Lazarus HM et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993;82:2605-10.
7. Shpall EJ, Jones RB, Bearman SI et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 1994;12:28-36.
8. Brugger W, Bross K, Glatt M et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994;83:636-40.
9. Brenner MK, Rill DR, Moen RC et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993;341:85-6.
10. Deisseroth AB, Zu Z, Claxton D et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994;83:3068-76.
11. Rill DR, Santana VM, Roberts WM et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994; 84:380-83.
12. + marrow cells in patients with breast cancer or neuro-blastoma. Blood 1991;77:1717-22.
13. + bone marrow progenitor cells in patients with non-Hodgkin's lymphoma. Blood 1995;85:1647-54.
14. Shpall EJ, LeMaistre CF, Holland K et al. A prospective randomized trial of buffy coat versus CD34-selected autologous bone mar-row support in high-risk breast cancer patients receiving high-dose chemotherapy. Blood 1997; 90:4313-20.
15. Schiller G, Vescio R, Freytes C et al. Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma. Bone Marrow Transplant 1998;21:141-45.
16. + cell transplantation for patients with advanced lymphoma: effects of overnight storage on peripheral blood progenitor cell enrichment and engraftment. Bone Marrow Transplant 1998; 21:337-43.
17. Alcorn MJ, Holyoake TL, Richmond LJ et al. CD34-positive cells isolated from cryopreserved peripheral-blood progenitor cells can be expanded ex vivo and used for transplantation with little or no toxicity. J Clin Oncol 1996;14:1839-47.
18. + cells from cryopreserved peripheral blood stem cells after thawing: technical aspects and clinical use. Bone Marrow Transplant 1996;17:259-64.
19. Holyoake TL, Alcorn MJ, Richmond L et al. CD34 positive PBPC expanded ex vivo may not provide durable engraftment following myeloablative chemoradiotherapy regimens. Bone Marrow Transplant 1997;19:1095-101.
20. + cells can be selected efficiently from cryopreserved peripheral blood progenitor cells and can retain their proliferative potential. J Hematother 1997;6:501-10.
21. + cells isolated from frozen human apheresis products. J Hematother 1997;6:69-75.
22. Rowley SD. Recombinant human deoxyribonuclease for hematopoietic stem cell processing. J Hematother 1995;4:99-104.
23. Holyoake TL, Alcorn MJ. CD34 positive haemopoietic cells: biology and clinical applications. Blood Rev 1994;8:113-124.
24. Holyoake TL, Alcorn MJ, Richmond LJ. CD34 selection and ex vivo expansion of haemopoietic progenitor cells: a review of laboratory methodology. Hematology 1997;2:261-80.
25. Breems DA, Blokland EA, Beben E et al. Frequency analysis of human primitive haematopoietic stem cell subsets using a cobble-stone area forming cell assay. Leukemia 1994; 8:1095-104.
26. Rowley SD, Bensinger WI, Gooley TA et al. Effect of cell concentration on bone marrow and peripheral blood stem cell cryopreservation. Blood 1994;83:2731-6.
27. Smith DM, Weisenburger DD, Bierman P et al. Acute renal failure associated with autologous bone marrow transplantation. Bone Marrow Transplant 1987;2:195-201.
28. Vriesendorp R, Aalders JG, Sleijfer T et al. Effective high-dose chemotherapy with autologous bone marrow infusion in resistant ovarian cancer. Gynecol Oncol 1984;17:271-6.
29. O'Donnell JR, Burnett AK, Sheehan T et al. Safety of dimethylsulphoxide. Lancet 1981;1:498.